Dermatologic Conditions of the Early Post-Transplant Period in Hematopoietic Stem Cell Transplant Recipients

  • Cynthia X. Wang
  • Milan J. Anadkat
  • Amy C. Musiek
Review Article


Hematopoietic stem cell transplants (HSCTs) are used to treat a variety of conditions, including hematologic malignancies, bone marrow failure syndromes, and immunodeficiencies. Over 60,000 HSCTs are performed annually worldwide, and the numbers continue to increase. Indeed, as new conditioning regimens develop, more and more individuals, including those of older age, will be eligible for transplants. Nevertheless, although HSCTs are clearly a life-saving and necessary treatment for thousands of patients per year, there is still substantial morbidity and mortality associated with the procedure. Of note, skin eruptions in the post-HSCT period are frequent and often significantly reduce quality of life in recipients. Moreover, these cutaneous findings sometimes herald an underlying systemic condition, presenting possible opportunities for timelier intervention. Dermatologists therefore play a vital role in distinguishing life-threatening conditions from benign issues and prompting recognition of critical complications earlier in their course. This article aims to review the major dermatologic conditions occurring in the early post-HSCT period.



The authors thank Dr. Leo Shmuylovich, MD/PhD, and Dr. Douglas Laurain, MD, for assisting with select photographs in this review.

Compliance with Ethical Standards


No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of Interest

CXW, MJA, and ACM have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transpl. 2016;51(6):778–85.CrossRefGoogle Scholar
  2. 2.
    Champlain A, Bach D, West D, Mehta J, Cotliar J. Dermatology consultation and change in diagnosis and/or management of patients after allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol. 2014;70(5):AB115.Google Scholar
  3. 3.
    Zulu S, Kenyon M. Principles of Conditioning Therapy and Cell Infusion. In: Kenyon M, Babic A, editors. The European blood and marrow transplantation textbook for nurses: under the auspices of EBMT. Cham: Springer International Publishing; 2018. p. 89–96.CrossRefGoogle Scholar
  4. 4.
    Blaise D, Vey N, Faucher C, Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2007;92(4):533–41.CrossRefGoogle Scholar
  5. 5.
    Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, et al. Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results. Biol Blood Marrow Transpl. 2017;23(2):285–92.CrossRefGoogle Scholar
  6. 6.
    Sengsayadeth S, Savani BN, Blaise D, Mohty M. Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source. Semin Hematol. 2016;53(2):111–4.CrossRefGoogle Scholar
  7. 7.
    Valadkhani B, Kargar M, Ashouri A, Hadjibabaie M, Gholami K, Ghavamzadeh A. The risk factors for cytomegalovirus reactivation following stem cell transplantation. J Res Pharm Pract. 2016;5(1):63–9.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Danby R, Rocha V. Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol. 2014;5:68.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2016;22(8):505–14.CrossRefGoogle Scholar
  10. 10.
    Jaing T-H. Complications of haematopoietic stem cell transplantation. ISBT Sci Ser. 2011;6(2):332–6.CrossRefGoogle Scholar
  11. 11.
    Spitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transpl. 2015;50(4):469–75.CrossRefGoogle Scholar
  12. 12.
    Chen Y, Xu LP, Liu KY, Chen H, Chen YH, Zhang XH, et al. High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation. Eur J Haematol. 2016;96(5):517–26.CrossRefGoogle Scholar
  13. 13.
    Takatsuka H, Takemoto Y, Yamada S, Wada H, Tamura S, Fujimori Y, et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transpl. 2000;26(4):419–26.CrossRefGoogle Scholar
  14. 14.
    Oyama Y, Cohen B, Traynor A, Brush M, Rodriguez J, Burt RK. Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transpl. 2002;29(1):81–5.CrossRefGoogle Scholar
  15. 15.
    Ravoet C, Feremans W, Husson B, Majois F, Kentos A, Lambermont M, et al. Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. Bone Marrow Transpl. 1996;18(5):943–7.Google Scholar
  16. 16.
    Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, et al. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood Marrow Transpl. 2013;19(9):1368–73.CrossRefGoogle Scholar
  17. 17.
    Gutierrez-Garcia G, Rovira M, Magnano L, Rosinol L, Bataller A, Suarez-Lledo M, et al. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. Bone Marrow Transpl. 2018. CrossRefGoogle Scholar
  18. 18.
    Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transpl. 1995;16(1):175–82.Google Scholar
  19. 19.
    Madero L, Vicent MG, Sevilla J, Prudencio M, Rodriguez F, Diaz MA. Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation. Bone Marrow Transpl. 2002;30(6):355–8.CrossRefGoogle Scholar
  20. 20.
    Koreth J, Biernacki M, Aldridge J, Kim HT, Alyea EP 3rd, Armand P, et al. Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transpl. 2011;17(3):421–8.CrossRefGoogle Scholar
  21. 21.
    Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ, et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transpl. 2005;11(7):542–50.CrossRefGoogle Scholar
  22. 22.
    Ileri T, Unal Ince E, Cakmakli H, Uysal Z, Gencturk Z, Ertem M. Evaluation of engraftment syndrome in children following full-matched related donor hematopoietic stem cell transplantations. Pediatr Transpl. 2016;20(4):581–9.CrossRefGoogle Scholar
  23. 23.
    Omer AK, Kim HT, Yalamarti B, McAfee SL, Dey BR, Ballen KK, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation in adults. Am J Hematol. 2014;89(7):698–705.CrossRefGoogle Scholar
  24. 24.
    Chang L, Frame D, Braun T, Gatza E, Hanauer DA, Zhao S, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transpl. 2014;20(9):1407–17.CrossRefGoogle Scholar
  25. 25.
    Moreb JS, Kubilis PS, Mullins DL, Myers L, Youngblood M, Hutcheson C. Increased frequency of autoaggression syndrome associated with autologous stem cell transplantation in breast cancer patients. Bone Marrow Transpl. 1997;19(2):101–6.CrossRefGoogle Scholar
  26. 26.
    Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB, et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res. 2009;15(13):4499–507.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Morishima M, Nobeyama Y, Kamiyama Y, Nakagawa H. Case of engraftment syndrome appearing as scratch dermatitis. J Dermatol. 2018;45(2):e25–6.CrossRefGoogle Scholar
  28. 28.
    Champlain A, Frankfurt O, West D, Gerami P, Guitart J, Mehta J, et al. Clinical features of cutaneous pre-engraftment syndrome in patients receiving umbilical cord blood stem cell transplantation. Biol Blood Marrow Transpl. 2014;20(2):S263.CrossRefGoogle Scholar
  29. 29.
    Mossad S, Kalaycio M, Sobecks R, Pohlman B, Andresen S, Avery R, et al. Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection. Bone Marrow Transpl. 2005;35(4):375–81.CrossRefGoogle Scholar
  30. 30.
    Kanda J, Kaynar L, Kanda Y, Prasad VK, Parikh SH, Lan L, et al. Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. Bone Marrow Transpl. 2013;48(7):926–31.CrossRefGoogle Scholar
  31. 31.
    Jang KT, Song KY, Kim BK. Histological features and immune cell changes in skin lesions of engraftment syndrome of children undergoing hematopoietic stem cell transplantation. Histol Histopathol. 2012;27(2):235–40.PubMedGoogle Scholar
  32. 32.
    Horn TD, Redd JV, Karp JE, Beschorner WE, Burke PJ, Hood AF. Cutaneous eruptions of lymphocyte recovery. Arch Dermatol. 1989;125(11):1512–7.CrossRefGoogle Scholar
  33. 33.
    Horn TD. Acute cutaneous eruptions after marrow ablation: roses by other names? J Cutan Pathol. 1994;21(5):385–92.CrossRefGoogle Scholar
  34. 34.
    Horn T, Lehmkuhle MA, Gore S, Hood A, Burke P. Systemic cytokine administration alters the histology of the eruption of lymphocyte recovery. J Cutan Pathol. 1996;23(3):242–6.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Hurabielle C, Sbidian E, Beltraminelli H, Bouchindhomme B, Chassagne-Clement C, Balme B, et al. Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients. Hum Pathol. 2018;71:100–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Bauer DJ, Hood AF, Horn TD. Histologic comparison of autologous graft-vs-host reaction and cutaneous eruption of lymphocyte recovery. Arch Dermatol. 1993;129(7):855–8.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Gibney MD, Penneys NS, Nelson-Adesokan P. Cutaneous eruption of lymphocyte recovery mimicking mycosis fungoides in a patient with acute myelocytic leukemia. J Cutan Pathol. 1995;22(5):472–5.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Nellen RG, van Marion AM, Frank J, Poblete-Gutierrez P, Steijlen PM. Eruption of lymphocyte recovery or autologous graft-versus-host disease? Int J Dermatol. 2008;47(Suppl 1):32–4.CrossRefGoogle Scholar
  39. 39.
    Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21(3):389–401.CrossRefGoogle Scholar
  40. 40.
    Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007;150(4):197–214.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2012;18(8):1150–63.CrossRefGoogle Scholar
  42. 42.
    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15(6):825–8.Google Scholar
  43. 43.
    Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855–64.CrossRefGoogle Scholar
  44. 44.
    Ringden O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for blood and marrow transplantation (EBMT). Leuk Lymphoma. 1996;24(1–2):71–9.CrossRefGoogle Scholar
  45. 45.
    Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol. 2011;65(4):726–32.CrossRefGoogle Scholar
  46. 46.
    Friedman KJ, LeBoit PE, Farmer ER. Acute follicular graft-vs-host reaction. A distinct clinicopathologic presentation. Arch Dermatol. 1988;124(5):688–91.CrossRefGoogle Scholar
  47. 47.
    Firoz BF, Lee SJ, Nghiem P, Qureshi AA. Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. Arch Dermatol. 2006;142(2):175–82.CrossRefGoogle Scholar
  48. 48.
    Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol. 1998;134(5):602–12.CrossRefGoogle Scholar
  49. 49.
    Lehman JS, Gibson LE, el-Azhary RA, Chavan RN, Hashmi SK, Lohse CM, et al. Acute cutaneous graft-vs.-host disease compared to drug hypersensitivity reaction with vacuolar interface changes: a blinded study of microscopic and immunohistochemical features. J Cutan Pathol. 2015;42(1):39–45.CrossRefGoogle Scholar
  50. 50.
    Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis. 2007;2:35.PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Sullivan KM, Deeg HJ, Sanders J, Klosterman A, Amos D, Shulman H, et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood. 1986;67(4):1172–5.PubMedGoogle Scholar
  52. 52.
    Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007;109(7):2751–8.PubMedGoogle Scholar
  53. 53.
    Shiohara J, Takata M, Shiohara M, Ito T, Ishida F. Hyperacute graft-versus-host disease: histological assessment of skin biopsy specimens from 19 cases. Clin Exp Dermatol. 2012;37(4):335–40.CrossRefGoogle Scholar
  54. 54.
    Kim DH, Sohn SK, Kim JG, Suh JS, Lee KS, Lee KB. Clinical impact of hyperacute graft-versus-host disease on results of allogeneic stem cell transplantation. Bone Marrow Transpl. 2004;33(10):1025–30.CrossRefGoogle Scholar
  55. 55.
    Deeg HJ, Antin JH. The clinical spectrum of acute graft-versus-host disease. Semin Hematol. 2006;43(1):24–31.CrossRefGoogle Scholar
  56. 56.
    Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765–70.PubMedGoogle Scholar
  57. 57.
    Weyers W, Metze D. Histopathology of drug eruptions—general criteria, common patterns, and differential diagnosis. Dermatol Pract Concept. 2011;1(1):33–47.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med. 2012;366(26):2492–501.CrossRefGoogle Scholar
  59. 59.
    Mays SR, Kunishige JH, Truong E, Kontoyiannis DP, Hymes SR. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg. 2007;26(3):155–62.CrossRefGoogle Scholar
  60. 60.
    Cices AD, Carneiro C, Majewski S, et al. Differentiating skin rash after stem cell transplantation: graft versus host disease, cutaneous reactions to drugs and viral exanthema. Curr Dermatol Rep. 2016;5(1):12–7.CrossRefGoogle Scholar
  61. 61.
    Cetkovska P, Pizinger K, Cetkovsky P. High-dose cytosine arabinoside-induced cutaneous reactions. J Eur Acad Dermatol Venereol. 2002;16(5):481–5.CrossRefGoogle Scholar
  62. 62.
    Gerson D, Sriganeshan V, Alexis JB. Cutaneous drug eruptions: a 5-year experience. J Am Acad Dermatol. 2008;59(6):995–9.CrossRefGoogle Scholar
  63. 63.
    Weaver J, Bergfeld WF. Quantitative analysis of eosinophils in acute graft-versus-host disease compared with drug hypersensitivity reactions. Am J Dermatopathol. 2010;32(1):31–4.CrossRefGoogle Scholar
  64. 64.
    Marra DE, McKee PH, Nghiem P. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. J Am Acad Dermatol. 2004;51(4):543–6.CrossRefGoogle Scholar
  65. 65.
    Bircher AJ. Exanthematous (maculopapular) drug eruption. In: UpToDate. Waltham. Accessed 27 June 2018.
  66. 66.
    Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7(6):803–13 (quiz 14-5).CrossRefGoogle Scholar
  67. 67.
    Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.CrossRefGoogle Scholar
  68. 68.
    Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012;66(6):995–1003.CrossRefGoogle Scholar
  69. 69.
    Boull CL, Hylwa SA, Sajic D, Wagner JE, Tolar J, Hook KP. Toxic epidermal necrolysis in recessive dystrophic epidermolysis bullosa following bone marrow transplantation. J Pediatr. 2016;173:242–4.PubMedCentralCrossRefPubMedGoogle Scholar
  70. 70.
    Schaich M, Schakel K, Illmer T, Ehninger G, Bornhauser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2003;82(5):303–4.PubMedGoogle Scholar
  71. 71.
    Gomulka J, Wilson BD, Joyce JC. Toxic epidermal necrolysis due to voriconazole: case report and review. Dermatol Online J. 2014;20(9).Google Scholar
  72. 72.
    McDonald BJ, Singer JW, Bianco JA. Toxic epidermal necrolysis possibly linked to aztreonam in bone marrow transplant patients. Ann Pharmacother. 1992;26(1):34–5.CrossRefGoogle Scholar
  73. 73.
    Takeda H, Mitsuhashi Y, Kondo S, Kato Y, Tajima K. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol. 1997;24(10):635–41.CrossRefGoogle Scholar
  74. 74.
    Birch J, Chamlin S, Duerst R, Jacobsohn D. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome in a hematopoietic stem cell transplant recipient. Pediatr Blood Cancer. 2008;50(6):1278–9.CrossRefGoogle Scholar
  75. 75.
    Zakrzewski JL, Lentini G, Such U, Duerr A, Tran V, Guenzelmann S, et al. Toxic epidermal necrolysis: differential diagnosis of an epidermolytic dermopathy in a hematopoietic stem cell transplant recipient. Bone Marrow Transpl. 2002;30(5):331–3.CrossRefGoogle Scholar
  76. 76.
    Friedman HZ, Arias AM, Catchatourian R, Fretzin DF. Toxic epidermal necrolysis following bone marrow transplantation. Cutis. 1984;34(2):158–62.PubMedGoogle Scholar
  77. 77.
    Villada G, Roujeau JC, Cordonnier C, Bagot M, Kuentz M, Wechsler J, et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol. 1990;23(5 Pt 1):870–5.CrossRefGoogle Scholar
  78. 78.
    Hilgendorf I, Casper J, Sviland L, Prall F, Junghanss C, Freund M, et al. Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transpl. 2007;39(4):245–6.CrossRefGoogle Scholar
  79. 79.
    Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–7.CrossRefGoogle Scholar
  80. 80.
    Roujeau JC, Bastuji-Garin S. Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Saf. 2011;2(3):87–94.PubMedCentralCrossRefPubMedGoogle Scholar
  81. 81.
    Kim KJ, Lee DP, Suh HS, Lee MW, Choi JH, Moon KC, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol. 2005;85(6):497–502.PubMedGoogle Scholar
  82. 82.
    Kelemen JJ 3rd, Cioffi WG, McManus WF, Mason AD Jr, Pruitt BA Jr. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg. 1995;180(3):273–8.PubMedGoogle Scholar
  83. 83.
    Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204(5):503–12.PubMedCentralCrossRefPubMedGoogle Scholar
  84. 84.
    Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and Toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514–22.PubMedCentralCrossRefPubMedGoogle Scholar
  85. 85.
    Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58(1):33–40.CrossRefGoogle Scholar
  86. 86.
    Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144–8.CrossRefGoogle Scholar
  87. 87.
    Liu W, Nie X, Zhang L. A retrospective analysis of Stevens-Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids. Int J Dermatol. 2016;55(12):1408–13.CrossRefGoogle Scholar
  88. 88.
    Hirahara K, Kano Y, Sato Y, Horie C, Okazaki A, Ishida T, et al. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J Am Acad Dermatol. 2013;69(3):496–8.CrossRefGoogle Scholar
  89. 89.
    Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–9.CrossRefGoogle Scholar
  90. 90.
    Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 2005;16(7):1210–1.CrossRefGoogle Scholar
  91. 91.
    Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol. 1991;24(3):457–61.CrossRefGoogle Scholar
  92. 92.
    Demircay Z, Gurbuz O, Alpdogan TB, Yucelten D, Alpdogan O, Kurtkaya O, et al. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol. 1997;36(8):593–8.CrossRefGoogle Scholar
  93. 93.
    Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transpl. 2013;48(5):646–50.CrossRefGoogle Scholar
  94. 94.
    Martorell-Calatayud A, Sanmartin O, Botella-Estrada R, Balmer NN, Serra-Guillen C, Gomez-Moyano E, et al. Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features. J Am Acad Dermatol. 2011;64(6):1092–103.CrossRefGoogle Scholar
  95. 95.
    Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol. 2014;71(2):203.e1–12 (quiz 15-6).CrossRefGoogle Scholar
  96. 96.
    Bandini G, Belardinelli A, Rosti G, Calori E, Motta MR, Rizzi S, et al. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transpl. 1994;13(5):577–81.Google Scholar
  97. 97.
    Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181–9.CrossRefGoogle Scholar
  98. 98.
    Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253–62.CrossRefGoogle Scholar
  99. 99.
    Vaiman M, Lazarovitch T, Heller L, Lotan G. Ecthyma gangrenosum and ecthyma-like lesions: review article. Eur J Clin Microbiol Infect Dis. 2015;34(4):633–9.CrossRefGoogle Scholar
  100. 100.
    Koo SH, Lee JH, Shin H, Lee JI. Ecthyma gangrenosum in a previously healthy infant. Arch Plastic Surg. 2012;39(6):673–5.CrossRefGoogle Scholar
  101. 101.
    Vaiman M, Lasarovitch T, Heller L, Lotan G. Ecthyma gangrenosum versus ecthyma-like lesions: should we separate these conditions? Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(4):69–72.PubMedGoogle Scholar
  102. 102.
    Greene SL, Su WP, Muller SA. Ecthyma gangrenosum: report of clinical, histopathologic, and bacteriologic aspects of eight cases. J Am Acad Dermatol. 1984;11(5 Pt 1):781–7.CrossRefGoogle Scholar
  103. 103.
    Martinez-Longoria CA, Rosales-Solis GM, Ocampo-Garza J, Guerrero-Gonzalez GA, Ocampo-Candiani J. Ecthyma gangrenosum: a report of eight cases. An Bras Dermatol. 2017;92(5):698–700.PubMedCentralCrossRefPubMedGoogle Scholar
  104. 104.
    McManus AT, Mason AD Jr, McManus WF, Pruitt BA Jr. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur J Clin Microbiol. 1985;4(2):219–23.CrossRefGoogle Scholar
  105. 105.
    Abdelkefi A, Torjman L, Ladeb S, Sghaier Z, Jeddi R, Lakhal A, et al. Isolated extramedullary relapse in the breast of a patient with acute myeloid leukemia following allogeneic stem cell transplantation: case report and review of the literature. Int J Hematol. 2007;85(2):149–53.CrossRefGoogle Scholar
  106. 106.
    Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011;25(1):101–16.CrossRefGoogle Scholar
  107. 107.
    Mays SR, Bogle MA, Bodey GP. Cutaneous fungal infections in the oncology patient: recognition and management. Am J Clin Dermatol. 2006;7(1):31–43.CrossRefGoogle Scholar
  108. 108.
    Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis. 2001;33(12):1959–67.CrossRefGoogle Scholar
  109. 109.
    Burke VE, Lopez FA. Approach to skin and soft tissue infections in non-HIV immunocompromised hosts. Curr Opin Infect Dis. 2017;30(4):354–63.CrossRefGoogle Scholar
  110. 110.
    Guarana M, Nucci M. Acute disseminated candidiasis with skin lesions: a systematic review. Clin Microbiol Infect. 2018;24(3):246–50.CrossRefGoogle Scholar
  111. 111.
    Kauffman CA. Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults. In: UpToDate. Accessed 27 June 2018.
  112. 112.
    Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005;18(1):44–69.PubMedCentralCrossRefPubMedGoogle Scholar
  113. 113.
    Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65(5):453–64.CrossRefGoogle Scholar
  114. 114.
    van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol. 1998;36(11):3115–21.PubMedCentralPubMedGoogle Scholar
  115. 115.
    Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med. 1987;317(18):1105–8.CrossRefGoogle Scholar
  116. 116.
    Johnson AS, Ranson M, Scarffe JH, Morgenstern GR, Shaw AJ, Oppenheim BA. Cutaneous infection with Rhizopus oryzae and Aspergillus niger following bone marrow transplantation. J Hosp Infect. 1993;25(4):293–6.CrossRefGoogle Scholar
  117. 117.
    Bernardeschi C, Foulet F, Ingen-Housz-Oro S, Ortonne N, Sitbon K, Quereux G, et al. Cutaneous invasive aspergillosis: retrospective multicenter study of the french invasive-aspergillosis registry and literature review. Medicine (Baltimore). 2015;94(26):e1018.PubMedCentralCrossRefPubMedGoogle Scholar
  118. 118.
    Chakrabarti A, Gupta V, Biswas G, Kumar B, Sakhuja VK. Primary cutaneous aspergillosis: our experience in 10 years. J Infect. 1998;37(1):24–7.CrossRefGoogle Scholar
  119. 119.
    Reischies F, Hoenigl M. The role of surgical debridement in different clinical manifestations of invasive aspergillosis. Mycoses. 2014;57(Suppl 2):1–14.CrossRefGoogle Scholar
  120. 120.
    Bodey GP, Boktour M, Mays S, Duvic M, Kontoyiannis D, Hachem R, et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol. 2002;47(5):659–66.CrossRefGoogle Scholar
  121. 121.
    Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38(9):1237–42.CrossRefGoogle Scholar
  122. 122.
    Zimmerli W, Zarth A, Gratwohl A, Speck B. Neutrophil function and pyogenic infections in bone marrow transplant recipients. Blood. 1991;77(2):393–9.PubMedGoogle Scholar
  123. 123.
    Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O’Gorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99(12):4357–63.CrossRefGoogle Scholar
  124. 124.
    Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol. 2012;5:46.PubMedCentralCrossRefPubMedGoogle Scholar
  125. 125.
    Lin R, Liu Q. Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2013;6:94.PubMedCentralCrossRefPubMedGoogle Scholar
  126. 126.
    Lewis DJ, Schlichte MJ, Dao H Jr. Atypical disseminated herpes zoster: management guidelines in immunocompromised patients. Cutis. 2017;100(5):321 (324, 330).PubMedGoogle Scholar
  127. 127.
    Kadakia MP, Rybka WB, Stewart JA, Patton JL, Stamey FR, Elsawy M, et al. Human herpesvirus 6: infection and disease following autologous and allogeneic bone marrow transplantation. Blood. 1996;87(12):5341–54.PubMedGoogle Scholar
  128. 128.
    Ogata M, Kikuchi H, Satou T, Kawano R, Ikewaki J, Kohno K, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis. 2006;193(1):68–79.CrossRefGoogle Scholar
  129. 129.
    Gotoh M, Yoshizawa S, Katagiri S, Suguro T, Asano M, Kitahara T, et al. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease. Transpl Infect Dis. 2014;16(3):440–9.CrossRefGoogle Scholar
  130. 130.
    Drago F, Ciccarese G, Broccolo F, Cozzani E, Parodi A. Atypical exanthems associated with HHV-6 reactivation after hematopoietic cell transplantation. J Clin Virol. 2015;72:119–21.CrossRefGoogle Scholar
  131. 131.
    de Pagter PJ, Schuurman R, Visscher H, de Vos M, Bierings M, van Loon AM, et al. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol Blood Marrow Transpl. 2008;14(7):831–9.CrossRefGoogle Scholar
  132. 132.
    Betts BC, Young JA, Ustun C, Cao Q, Weisdorf DJ. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? Biol Blood Marrow Transpl. 2011;17(10):1562–8.CrossRefGoogle Scholar
  133. 133.
    Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40(7):932–40.CrossRefGoogle Scholar
  134. 134.
    Breuer S, Rauch M, Matthes-Martin S, Lion T. Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients. Mol Diagn Ther. 2012;16(2):63–77.CrossRefGoogle Scholar
  135. 135.
    Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230–9.PubMedCentralCrossRefPubMedGoogle Scholar
  136. 136.
    Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–9.PubMedCentralCrossRefPubMedGoogle Scholar
  137. 137.
    Min CK. The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol. 2011;46(2):80–7.PubMedCentralCrossRefPubMedGoogle Scholar
  138. 138.
    Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124(3):374–84.PubMedCentralCrossRefPubMedGoogle Scholar
  139. 139.
    Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood. 2012;120(13):2545–52 (quiz 774).PubMedCentralCrossRefPubMedGoogle Scholar
  140. 140.
    Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol. 2018;19(1):33–50.CrossRefGoogle Scholar
  141. 141.
    Pinney SS, Alousi AM, Hymes SR. Clinical presentation of nonsclerotic epidermal chronic graft-versus-host disease and hair and nail changes. In: Cotliar JA, editor. Atlas of graft-versus-host disease: approaches to diagnosis and treatment. Cham: Springer International Publishing; 2017. p. 69–91.CrossRefGoogle Scholar
  142. 142.
    Penas PF, Fernandez-Herrera J, Garcia-Diez A. Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol. 2004;5(6):403–16.CrossRefGoogle Scholar
  143. 143.
    Zuo RC, Naik HB, Steinberg SM, Baird K, Mitchell SA, Kuzmina Z, et al. Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease. JAMA Dermatol. 2015;151(1):23–32.CrossRefGoogle Scholar
  144. 144.
    Ceovic R, Desnica L, Pulanic D, Serventi Seiwerth R, Ilic I, Grce M, et al. High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease. Croat Med J. 2016;57(3):229–38.PubMedCentralCrossRefPubMedGoogle Scholar
  145. 145.
    Huang JT, Song JS, Hawryluk EB, London WB, Guo D, Sridharan M, et al. Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. J Am Acad Dermatol. 2018;79(2):230–7.CrossRefGoogle Scholar
  146. 146.
    Nadeem S, Hymes S, Kebriaei P, Abruzzo L, Curry JL, Duvic M. Alopecia areata after HLA-identical BMT from an affected, sibling donor. Bone Marrow Transpl. 2014;49(4):592–4.CrossRefGoogle Scholar
  147. 147.
    DePry JL, Vyas R, Lazarus HM, Caimi PF, Gerstenblith MR, Bordeaux JS. Cutaneous malignant neoplasms in hematopoietic cell transplant recipients: a systematic review. JAMA Dermatol. 2015;151(7):775–82.CrossRefGoogle Scholar
  148. 148.
    Omland SH, Gniadecki R, Haedersdal M, Helweg-Larsen J, Omland LH. Skin cancer risk in hematopoietic stem-cell transplant recipients compared with background population and renal transplant recipients: a population-based cohort study. JAMA Dermatol. 2016;152(2):177–83.CrossRefGoogle Scholar
  149. 149.
    Rambhia PH, Conic RZ, Atanaskova-Mesinkovska N, Piliang M, Bergfeld WF. Role of graft versus host disease in the development of secondary skin cancers in hematopoietic stem cell transplant recipients: a meta-analysis. J Am Acad Dermatol. 2018;79(2):378–80.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Cynthia X. Wang
    • 1
  • Milan J. Anadkat
    • 1
    • 2
  • Amy C. Musiek
    • 1
    • 2
  1. 1.Washington University School of MedicineSt. LouisUSA
  2. 2.Division of DermatologyWashington University School of MedicineSt. LouisUSA

Personalised recommendations